Correlation of cyp2c19 phenotype with voriconazole plasma concentration in children

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 5, 2013, Pages

  Narita, Atsushi ^a   Muramatsu, Hideki ^a   Sakaguchi, Hirotoshi ^a   Doisaki, Sayoko ^a   Tanaka, Makito ^a   Hama, Asahito ^a   Shimada, Akira ^a   Takahashi, Yoshiyuki ^a   Yoshida, Nao ^b   Matsumoto, Kimikazu ^b   Kato, Koji ^b   Kudo, Kazuko ^c   Furukawa Hibi, Yoko ^a   Yamada, Kiyofumi ^a   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

Author keywords

CYP2C19; Drug monitoring; Fungal infection; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOTOXICITY; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYP2C19 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPEROSMOLARITY; HYPONATREMIA; HYPOOSMOLALITY; INAPPROPRIATE VASOPRESSIN SECRETION; JAPANESE; LIVER TOXICITY; MALE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM URINE LEVEL; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFANT; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES;

EID: 84880294530     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182880eaa     Document Type: Article

References (18)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
2. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61: 17-25.
3. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172.
4. Miyakis S, van Hal SJ, Solvag CJ, et al. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit. 2010; 32:661-664.
5. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
6. Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007;9: 33-36.
7. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of america. Cli Infect Dis. 2008;46:327-360.
8. Hyland R, Jones BC, Smith DA. Identification of the cytochrome p450 enzymes involved in the n-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540-547.
9. Pennick GJ, Clark M, Sutton DA, et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 2003;47:2348-2350.
10. Pare G, Mehta SR, Yusuf S, et al. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704-1714.
11. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54:1050-1052.
12. Friberg LE, Ravva P, Karlsson MO, et al. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56:3032-3042.
13. Goldstein JA. Clinical relevance of genetic polymorphisms in the human cyp2c subfamily. Br J Clin Pharmacol. 2001;52:349-355.
14. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective cyp2c19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64.
15. Fukushima-Uesaka H, Saito Y, Maekawa K, et al. Genetic variations and haplotypes of cyp2c19 in a japanese population. Drug Metab Pharmacokinet. 2005;20:300-307.
16. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
17. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935-944.
18. Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in korean patients. Int J Infect Dis. 2011;15: e753-e758.